We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

38 hedge funds and large institutions have $6.77M invested in Cellectar Biosciences in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

0.04% less ownership

Funds ownership: 0.08% → 0.04% (-0.04%)

12% less funds holding

Funds holding: 43 → 38 (-5)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

54% less capital invested

Capital invested by funds: $14.9M → $6.77M (-$8.1M)

Holders
38
Holders Change
-5
Holders Change %
-11.63%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
5
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$457K
2
MS
Maven Securities
Jersey
+$367K
3
Franklin Resources
Franklin Resources
California
+$145K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$94.9K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$90.9K

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$4.66M
2
Renaissance Technologies
Renaissance Technologies
New York
-$574K
3
SM
Sabby Management
Florida
-$508K
4
GCP
GSA Capital Partners
United Kingdom
-$354K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$296K
Name Holding Trade Value Shares
Change 		Change in
Stake
CB
26
Commerce Bank
Missouri
$13K +$14.6K +48 New
UBS Group
27
UBS Group
Switzerland
$11K – – –
SC
28
Scotia Capital
Ontario, Canada
$10K +$11.3K +37 New
PNC Financial Services Group
29
PNC Financial Services Group
Pennsylvania
$9K – – –
TCM
30
Tradewinds Capital Management
Washington
$9K – – –
ASN
31
Advisory Services Network
Georgia
$9K +$10.1K +33 New
Osaic Holdings
32
Osaic Holdings
Arizona
$5K -$18.6K -61 -77%
JFGIW
33
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$5K – – –
US Bancorp
34
US Bancorp
Minnesota
$3K – – –
Wells Fargo
35
Wells Fargo
California
$3K – – –
CAPTRUST Financial Advisors
36
CAPTRUST Financial Advisors
North Carolina
$2K – – –
CCM
37
Consonance Capital Management
New York
– -$4.66M -13,043 Closed
SM
38
Sabby Management
Florida
– -$508K -1,422 Closed
GCP
39
GSA Capital Partners
United Kingdom
– -$354K -992 Closed
FIA
40
FNY Investment Advisers
New York
– -$262K -734 Closed
PAM
41
PVG Asset Management
Colorado
– -$230K -645 Closed
Envestnet Asset Management
42
Envestnet Asset Management
Illinois
– -$124K -348 Closed
VF
43
Virtu Financial
New York
– -$59K -166 Closed
Creative Planning
44
Creative Planning
Kansas
– -$36K -100 Closed
MSAM
45
Moloney Securities Asset Management
Missouri
– -$22K -62 Closed
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
– -$18K -50 Closed
ECM
47
ExodusPoint Capital Management
New York
– -$17K -48 Closed
Bank Julius Baer & Co
48
Bank Julius Baer & Co
Switzerland
– -$9K -25 Closed
1
2

CLRB Hedge Fund Activity: Q3 2021 in Review

38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2021, worth a combined $6.77M — down 54% from $14.9M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CLRB and 8 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.

The largest buyer was Morgan Stanley, adding an estimated $457K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $4.66M sold.

  • 38 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2021, down from 43 in Q2 2021.
  • Funds reported $6.77M of Cellectar Biosciences stock for Q3 2021, down 54% quarter-over-quarter.
  • 8 funds opened new Cellectar Biosciences positions in Q3 2021 and 12 closed out, a net change of -4 holders.
  • The largest Cellectar Biosciences buyer in Q3 2021 was Morgan Stanley, an estimated $457K added.
  • The largest Cellectar Biosciences seller in Q3 2021 was Consonance Capital Management, an estimated $4.66M sold.

Based on aggregated 13F filings for Q3 2021.